(Q42969280)

11 November 2017

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer (English)

1 reference

11 November 2017

2

1 reference

11 November 2017

1

Magali Terme

1 reference

11 November 2017

3

Julien Taieb

1 reference

11 November 2017

10 June 2013

1 reference

11 November 2017

1 reference

11 November 2017

2

1 reference

11 November 2017

8

1 reference

11 November 2017

e25156

1 reference

Modulation of immunity by antiangiogenic molecules in cancer

11 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782524

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782524

Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782524

Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782524

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782524

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782524

A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782524

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782524

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782524

Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24083078

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/ONCI.25156

1 reference

11 November 2017

1 reference

11 November 2017

1 reference

PMCID

3782524